{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG000","lowerLimit":"8.6","upperLimit":"NA","value":"10.6"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG001","lowerLimit":"2.4","upperLimit":"NA","value":"5.2"},{"groupId":"OG002","lowerLimit":"1.5","upperLimit":"6.2","value":"1.6"},{"comment":"Median and Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG003","lowerLimit":"2.1","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG004","lowerLimit":"1.9","upperLimit":"NA","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"TTNT was defined as the time from the date of first dose to the date of the first dose initiation of the next line of antineoplastic therapy, for any reason.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received TAK-981 60 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 1b, Part 1: TAK-981 60 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG001","title":"Phase 1b, Part 1: TAK-981 90 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG002","title":"Phase 1b, Part 1: TAK-981 90 mg QW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG003","title":"Phase 1b, Part 1: TAK-981 120 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG004","title":"Phase 1b, Part 1: TAK-981 120 mg QW + Mezagitamab 600 mg"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set included participants who received at least 1 dose, even if incomplete, of study drug.","reportingStatus":"POSTED","timeFrame":"From the date of first dose of study drug to the date of the first dose initiation of the next line of antineoplastic therapy (up to 12 months)","title":"Phases 1b, Part 1: Time to Next Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"months"}